BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $21,226 | +20.0% | 838 | +46.5% | 0.00% | – |
| Q1 2024 | $17,686 | -26.6% | 572 | -4.2% | 0.00% | – |
| Q4 2023 | $24,101 | +42.1% | 597 | -7.2% | 0.00% | – |
| Q3 2023 | $16,957 | +53.3% | 643 | 0.0% | 0.00% | – |
| Q2 2023 | $11,061 | +3.8% | 643 | 0.0% | 0.00% | – |
| Q1 2023 | $10,660 | +84.3% | 643 | -15.3% | 0.00% | – |
| Q4 2022 | $5,783 | -17.4% | 759 | +4.3% | 0.00% | – |
| Q3 2022 | $7,000 | 0.0% | 728 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | +133.3% | 728 | +225.0% | 0.00% | – |
| Q1 2022 | $3,000 | +200.0% | 224 | +173.2% | 0.00% | – |
| Q4 2021 | $1,000 | -99.6% | 82 | -98.5% | 0.00% | – |
| Q3 2021 | $249,000 | -21.2% | 5,338 | +2.8% | 0.00% | – |
| Q2 2021 | $316,000 | -15.1% | 5,194 | -13.8% | 0.00% | – |
| Q1 2021 | $372,000 | +24.4% | 6,028 | +43.7% | 0.00% | – |
| Q4 2020 | $299,000 | +29800.0% | 4,196 | +11555.6% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 36 | -12.2% | 0.00% | – |
| Q2 2020 | $1,000 | – | 41 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
| M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
| GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
| Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
| HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
| Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
| Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
| TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |